321 related articles for article (PubMed ID: 32593295)
1. Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson's disease.
Zhang J; Xiao L; Yang W
BMC Neurol; 2020 Jun; 20(1):255. PubMed ID: 32593295
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease.
Xu SQ; Li XF; Zhu HY; Liu Y; Fang F; Chen L
J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):743-747. PubMed ID: 24142730
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of combined sodium dimercaptopropanesulfonate and zinc treatment in neurological Wilson's disease with D-penicillamine treatment failure.
Chen D; Zhou X; Hou H; Feng L; Liu J; Liang Y; Lin X; Zhang J; Wu C; Liang X; Pei Z; Li X
Ther Adv Neurol Disord; 2016 Jul; 9(4):310-6. PubMed ID: 27366238
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of efficacy and safety of gandouling plus sodium dimercaptosulphonate in treatment of patients with neurological Wilson's disease from China.
Zhang J; Xie D; Li Y; Li L; Han H; Zhang J; Chen H; Wang M; Guo Y
J Tradit Chin Med; 2018 Oct; 38(5):781-786. PubMed ID: 32185997
[TBL] [Abstract][Full Text] [Related]
5. D-penicillamine versus zinc sulfate as first-line therapy for Wilson's disease.
Członkowska A; Litwin T; Karliński M; Dziezyc K; Chabik G; Czerska M
Eur J Neurol; 2014 Apr; 21(4):599-606. PubMed ID: 24447648
[TBL] [Abstract][Full Text] [Related]
6. Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson's disease in resource constrained setting.
Gupta P; Choksi M; Goel A; Zachariah U; Sajith KG; Ramachandran J; Chandy G; Kurian G; Rebekah G; Eapen CE
Indian J Gastroenterol; 2018 Jan; 37(1):31-38. PubMed ID: 29457214
[TBL] [Abstract][Full Text] [Related]
7. Combined dimercaptosuccinic acid and zinc treatment in neurological Wilson's disease patients with penicillamine-induced allergy or early neurological deterioration.
Zhu XQ; Li LY; Yang WM; Wang Y
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32809015
[TBL] [Abstract][Full Text] [Related]
8. Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Sinha S; Taly AB
J Neurol Sci; 2008 Jan; 264(1-2):129-32. PubMed ID: 17765927
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of Wilson's disease with penicillamine and zinc salts: a follow-up study].
Li M; Zhang YH; Qin J
Zhonghua Er Ke Za Zhi; 2003 Feb; 41(2):119-22. PubMed ID: 14759316
[TBL] [Abstract][Full Text] [Related]
10. Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.
Lowette KF; Desmet K; Witters P; Laleman W; Verslype C; Nevens F; Fevery J; Cassiman DM
Eur J Gastroenterol Hepatol; 2010 May; 22(5):564-71. PubMed ID: 20042865
[TBL] [Abstract][Full Text] [Related]
11. A study of susceptibility-weighted imaging in patients with Wilson disease during the treatment of metal chelator.
Zhou X; Xiao X; Li XH; Qin HL; Pu XY; Chen DB; Wu C; Feng L; Liang XL
J Neurol; 2020 Jun; 267(6):1643-1650. PubMed ID: 32060651
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of Gandouling plus low-dose D-penicillamine for treatment of Wilson's disease with neurological symptoms.
Zhang J; Li L; Chen H; Yang W
J Tradit Chin Med; 2018 Feb; 38(1):89-94. PubMed ID: 32185956
[TBL] [Abstract][Full Text] [Related]
13. A clinical study of Wilson's disease: The experience of a single Egyptian Paediatric Hepatology Unit.
El-Karaksy H; Fahmy M; El-Raziky MS; El-Hawary M; El-Sayed R; El-Koofy N; El-Mougy F; El-Hennawy A; El-Shabrawi M
Arab J Gastroenterol; 2011 Sep; 12(3):125-30. PubMed ID: 22055589
[TBL] [Abstract][Full Text] [Related]
14. Zinc monotherapy is effective in Wilson's disease patients with mild liver disease diagnosed in childhood: a retrospective study.
Ranucci G; Di Dato F; Spagnuolo MI; Vajro P; Iorio R
Orphanet J Rare Dis; 2014 Mar; 9():41. PubMed ID: 24661374
[TBL] [Abstract][Full Text] [Related]
15. Analysis of risk factors for neurological symptoms in patients with purely hepatic Wilson's disease at diagnosis.
Diao SP; Zhuang YS; Huang YQ; Zhou ZH; Liu AQ; Hong MF
BMC Neurol; 2023 Feb; 23(1):89. PubMed ID: 36855079
[TBL] [Abstract][Full Text] [Related]
16. Spatial investigation of the elemental distribution in Wilson's disease liver after d-penicillamine treatment by LA-ICP-MS.
Hachmöller O; Zibert A; Zischka H; Sperling M; Groba SR; Grünewald I; Wardelmann E; Schmidt HH; Karst U
J Trace Elem Med Biol; 2017 Dec; 44():26-31. PubMed ID: 28965585
[TBL] [Abstract][Full Text] [Related]
17. Early neurological worsening in patients with Wilson's disease.
Litwin T; Dzieżyc K; Karliński M; Chabik G; Czepiel W; Członkowska A
J Neurol Sci; 2015 Aug; 355(1-2):162-7. PubMed ID: 26071888
[TBL] [Abstract][Full Text] [Related]
18. Successful Splenectomy for Hypersplenism in Wilson's Disease: A Single Center Experience from China.
Li LY; Yang WM; Chen HZ; Wu YH; Fang X; Zhang J; Wang Z; Han YS; Wang Y
PLoS One; 2015; 10(4):e0124569. PubMed ID: 25910248
[TBL] [Abstract][Full Text] [Related]
19. Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilson's disease.
Dzieżyc K; Litwin T; Chabik G; Członkowska A
Funct Neurol; 2015; 30(4):264-8. PubMed ID: 26727705
[TBL] [Abstract][Full Text] [Related]
20. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
